• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

合成共聚物1可抑制针对髓鞘碱性蛋白的人T细胞系。

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.

作者信息

Teitelbaum D, Milo R, Arnon R, Sela M

机构信息

Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.

出版信息

Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):137-41. doi: 10.1073/pnas.89.1.137.

DOI:10.1073/pnas.89.1.137
PMID:1370347
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC48191/
Abstract

Copolymer 1 (Cop 1) is a synthetic basic random copolymer of amino acids that has been shown to be effective in suppression of experimental allergic encephalomyelitis and has been proposed as a candidate drug for multiple sclerosis. Cop 1 is immunologically cross reactive with myelin basic protein (BP) and was shown to inhibit murine BP-specific T-cell lines of various H-2 restrictions. In the present study these findings were extended to include human T-cell lines. Cop 1 competitively inhibited the proliferative responses and interleukin 2 secretion of six BP-specific T-cell lines and 13 clones with several DR restrictions and epitope specificities. Conversely, BP inhibited--albeit to a lesser extent--the response of all the Cop 1-specific T-cell lines and clones, irrespective of their DR restrictions. Another random copolymer of tyrosine, glutamic acid, and alanine, denoted TGA, had no effect on these lines. Neither Cop 1 nor BP inhibited the response of lines and clones specific for purified protein derivative. Cop 1 and BP exerted their cross-inhibitory effects only in the presence of antigen-presenting cells. These results suggest that Cop 1 can compete with BP for the binding to human major histocompatibility complex molecules. In view of recent studies implicating BP reactivity in multiple sclerosis, these findings suggest a possible mechanism for the beneficial effect of Cop 1 in this disease.

摘要

共聚体1(Cop 1)是一种合成的碱性氨基酸随机共聚物,已被证明在抑制实验性变应性脑脊髓炎方面有效,并被提议作为治疗多发性硬化症的候选药物。Cop 1与髓鞘碱性蛋白(BP)具有免疫交叉反应性,并被证明能抑制各种H-2限制型的小鼠BP特异性T细胞系。在本研究中,这些发现扩展到了人类T细胞系。Cop 1竞争性抑制了6个BP特异性T细胞系和13个具有多种DR限制和表位特异性的克隆的增殖反应及白细胞介素2分泌。相反,BP对所有Cop 1特异性T细胞系和克隆的反应也有抑制作用,尽管程度较小,且与它们的DR限制无关。另一种由酪氨酸、谷氨酸和丙氨酸组成的随机共聚物,称为TGA,对这些细胞系没有影响。Cop 1和BP都不抑制对纯化蛋白衍生物特异性的细胞系和克隆的反应。Cop 1和BP仅在存在抗原呈递细胞的情况下发挥交叉抑制作用。这些结果表明,Cop 1可以与BP竞争与人主要组织相容性复合体分子的结合。鉴于最近的研究表明BP反应性与多发性硬化症有关,这些发现提示了Cop 1在该疾病中产生有益作用的一种可能机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a65c/48191/0ec142f6ba9c/pnas01075-0156-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a65c/48191/0ec142f6ba9c/pnas01075-0156-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a65c/48191/0ec142f6ba9c/pnas01075-0156-a.jpg

相似文献

1
Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.合成共聚物1可抑制针对髓鞘碱性蛋白的人T细胞系。
Proc Natl Acad Sci U S A. 1992 Jan 1;89(1):137-41. doi: 10.1073/pnas.89.1.137.
2
Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.髓鞘碱性蛋白与合成共聚物1在活的抗原呈递细胞上与II类主要组织相容性复合体分子的直接结合——特异性与混杂性。
Proc Natl Acad Sci U S A. 1994 May 24;91(11):4872-6. doi: 10.1073/pnas.91.11.4872.
3
Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.合成共聚物Cop 1对T细胞针对髓鞘碱性蛋白反应的特异性抑制作用
Proc Natl Acad Sci U S A. 1988 Dec;85(24):9724-8. doi: 10.1073/pnas.85.24.9724.
4
Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking.共聚体1除了阻断主要组织相容性复合体外,还通过T细胞受体拮抗作用对抗髓鞘碱性蛋白的免疫显性表位82 - 100。
Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):634-9. doi: 10.1073/pnas.96.2.634.
5
Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation.共聚体-1诱导的抗原特异性T细胞活化抑制:对抗抗原呈递。
J Neuroimmunol. 1992 Mar;37(1-2):75-84. doi: 10.1016/0165-5728(92)90157-g.
6
T lymphocyte lines and clones selected against synthetic myelin basic protein 82-102 peptide from Japanese multiple sclerosis patients.针对来自日本多发性硬化症患者的合成髓鞘碱性蛋白82 - 102肽筛选出的T淋巴细胞系和克隆。
J Neuroimmunol. 1993 Jul;46(1-2):83-90. doi: 10.1016/0165-5728(93)90236-r.
7
Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules.合成共聚物1与纯化的HLA - DR分子的杂乱结合。
J Immunol. 1998 May 1;160(9):4386-97.
8
Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1.抗髓鞘碱性蛋白和抗合成共聚物1单克隆抗体的交叉反应及特异性
Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9528-32. doi: 10.1073/pnas.88.21.9528.
9
Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.共聚体-1与干扰素β-1b对髓鞘碱性蛋白免疫反应的相加作用。
J Neuroimmunol. 1995 Sep;61(2):185-93. doi: 10.1016/0165-5728(95)00085-g.
10
Novel synthetic amino acid copolymers that inhibit autoantigen-specific T cell responses and suppress experimental autoimmune encephalomyelitis.新型合成氨基酸共聚物可抑制自身抗原特异性T细胞反应并抑制实验性自身免疫性脑脊髓炎。
J Clin Invest. 2002 Jun;109(12):1635-43. doi: 10.1172/JCI15402.

引用本文的文献

1
HLA-A∗03:01 as predictive genetic biomarker for glatiramer acetate treatment response in multiple sclerosis: a retrospective cohort analysis.HLA-A∗03:01作为预测多发性硬化症中醋酸格拉替雷治疗反应的遗传生物标志物:一项回顾性队列分析
EBioMedicine. 2025 Jul 31;118:105873. doi: 10.1016/j.ebiom.2025.105873.
2
The epidemiology, pathology and pathogenesis of MS: Therapeutic implications.多发性硬化症的流行病学、病理学及发病机制:治疗意义
Neurotherapeutics. 2025 Feb 27:e00539. doi: 10.1016/j.neurot.2025.e00539.
3
Glatiramer acetate induces mast cell degranulation via MRGPRX2, implications for local and systemic adverse reactions.

本文引用的文献

1
Studies on the chemical basis of the antigenicity of proteins. 5. Synthesis, characterization and immunogenicity of some multichain and linear polypeptides containing tyrosine.蛋白质抗原性的化学基础研究。5. 一些含酪氨酸的多链和线性多肽的合成、表征及免疫原性
Biochem J. 1962 Oct;85(1):223-35. doi: 10.1042/bj0850223.
2
Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex.碱性致脑炎蛋白:在磺乙基葡聚糖凝胶上的简化纯化方法
FEBS Lett. 1970 May 1;7(4):317-320. doi: 10.1016/0014-5793(70)80193-4.
3
Isolation of myelin basic protein-reactive T-cell lines from normal human blood.
醋酸格拉替雷通过MRGPRX2诱导肥大细胞脱颗粒,这对局部和全身不良反应具有影响。
Allergy. 2024 Mar;79(3):758-761. doi: 10.1111/all.15978. Epub 2023 Dec 14.
4
Immunological Aspects of Approved MS Therapeutics.已获批多发性硬化症治疗药物的免疫学方面。
Front Immunol. 2019 Jul 11;10:1564. doi: 10.3389/fimmu.2019.01564. eCollection 2019.
5
Glatiramer Acetate Enhances Myeloid-Derived Suppressor Cell Function via Recognition of Paired Ig-like Receptor B.醋酸格拉替雷通过识别配对免疫球蛋白样受体 B 增强髓源性抑制细胞功能。
J Immunol. 2018 Sep 15;201(6):1727-1734. doi: 10.4049/jimmunol.1701450. Epub 2018 Aug 1.
6
The Evolving Mechanisms of Action of Glatiramer Acetate.醋酸格拉替雷作用机制的演变。
Cold Spring Harb Perspect Med. 2019 Feb 1;9(2):a029249. doi: 10.1101/cshperspect.a029249.
7
Disease-modifying therapies and infectious risks in multiple sclerosis.多发性硬化症的疾病修正治疗和感染风险。
Nat Rev Neurol. 2016 Apr;12(4):217-33. doi: 10.1038/nrneurol.2016.21. Epub 2016 Mar 4.
8
Teriflunomide and its mechanism of action in multiple sclerosis.特立氟胺及其在多发性硬化症中的作用机制。
Drugs. 2014 Apr;74(6):659-74. doi: 10.1007/s40265-014-0212-x.
9
First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.儿童多发性硬化的一线疾病修正治疗:全面概述。
Drugs. 2012 Jun 18;72(9):1195-211. doi: 10.2165/11634010-000000000-00000.
10
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.醋酸格拉替雷治疗多发性硬化症:作用机制的新观点。
CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000.
从正常人血液中分离髓鞘碱性蛋白反应性T细胞系。
Cell Immunol. 1983 Oct 15;81(2):435-40. doi: 10.1016/0008-8749(83)90250-2.
4
Current perspectives of neuroimmunologic disease: multiple sclerosis and experimental allergic encephalomyelitis (1,2).神经免疫性疾病的当前观点:多发性硬化症和实验性变态反应性脑脊髓炎(1,2)。
Clin Immunol Rev. 1981;1(4):581-697.
5
The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis.能够介导自身免疫性脑脊髓炎的可克隆抗原特异性T淋巴细胞系的快速分离。
Eur J Immunol. 1981 Mar;11(3):195-9. doi: 10.1002/eji.1830110307.
6
Automated synthesis of peptides.肽的自动化合成
Science. 1965 Oct 8;150(3693):178-85. doi: 10.1126/science.150.3693.178.
7
Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.一种合成多肽对实验性变应性脑脊髓炎的抑制作用
Eur J Immunol. 1971 Aug;1(4):242-8. doi: 10.1002/eji.1830010406.
8
Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer.一种合成碱性共聚物对恒河猴实验性变应性脑脊髓炎的抑制作用
Clin Immunol Immunopathol. 1974 Nov;3(2):256-62. doi: 10.1016/0090-1229(74)90012-9.
9
In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis.碱性脑(脊髓)炎原与能够抑制实验性变应性脑脊髓炎的合成碱性多肽之间的体内和体外免疫交叉反应。
Eur J Immunol. 1973 May;3(5):279-86. doi: 10.1002/eji.1830030506.
10
Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen.
Eur J Immunol. 1973 May;3(5):273-9. doi: 10.1002/eji.1830030505.